Brazil Cancer Immunotherapy Market Analysis

Brazil Cancer Immunotherapy Market Executive Analysis

Brazil's cancer immunotherapy market is at around $2.8 Bn in 2022 and is projected to reach $5.2 Bn in 2030, exhibiting a CAGR of 8.1% during the forecast period. With $64 Bn in revenues in 2022, up 11% from the previous year, the healthcare sector in Brazil is the largest in Latin America and ranks seventh globally. Similar to Denmark, Brazil has a comprehensive public health system known as the SUS (Sistema nico de Sade). In 2022, the SUS invested up to $25 Bn, which was 19% less than in 2021. This decrease was primarily the result of an improvement in the epidemiological scenario for COVID-19, which decreased costs with hospital assistance and epidemiological monitoring. Only 24% of Brazilians have access to private insurance, with approximately 76% relying solely on SUS.

The Brazilian Ministry of Health projects that 625,000 people will receive a cancer diagnosis in Brazil between 2021 and 2023 through the Brazilian National Cancer Institute (INCA), the country's national cancer institute. Due to its multifaceted nature, cancer requires thorough, intricate, and in-depth research in order to fully comprehend the mechanisms involved in its formation and progression and enable it to be controlled using the most up-to-date scientific knowledge.

Immunotherapy is a biological therapy that boosts the immune system's ability to fight against illnesses including cancer and other infections. There are several different types of immunotherapies, including cancer vaccines, adoptive cell transfers, immunological checkpoint inhibitors, and mostly monoclonal antibodies (mAbs). Once biological products with specific targets proved beneficial in treating a range of cancers, from solid tumours to hematological disorders, antibody-based medications were successfully developed. Using hybridoma technology, the first therapeutic mAbs were created from a single murine B cell clone. They are immunogenic while having great specificity, though. Production models for these antibodies were improved in order to address these problems, and the three main varieties created were chimeric (mouse/human), humanized, and entirely human.

Market Dynamics

Market Growth Drivers

In recent years, Brazil has made investments in its healthcare system with an emphasis on enhancing patient access and broadening the scope of accessible therapies. This investment is anticipated to aid in Brazil's cancer immunotherapy market expansion for cancer immunotherapy. Through programs like the Brazilian Cancer Society and the National Cancer Institute (INCA), the Brazilian government has supported cancer research. The development of novel cancer immunotherapy therapies is anticipated to be accelerated by this financing. Personalized medicine, which involves adjusting treatments to a patient's unique genetic profile and other features, is becoming more and more popular in Brazil. This strategy works well with immunotherapy treatments because they can be highly targeted to particular cancer types. A wide range of cancer immunotherapy medications, including novel therapies and combination therapies, are currently being developed. In the upcoming years, this pipeline is anticipated to fuel market expansion.

Market Restraints

Some individuals may not be able to receive cancer immunotherapy treatments because they cannot afford them or because their health insurance does not cover the fees due to the treatments' high cost. Cancer immunotherapy treatments are only partially reimbursed by the Brazilian government, which may restrict patient’s access to these medicines. Immunotherapy treatments have the potential to be very beneficial, but they also carry a risk of serious adverse effects, some of which might be life-altering for certain patients. The number of patients who are able or willing to receive these treatments may be constrained as a result. Brazil has a number of immunotherapy medicines available, however, some are currently awaiting approval or are not yet accessible there thus limiting the growth of the Brazil cancer immunotherapy market.

Competitive Landscape

Key Players

• Bioma (BRA)
• Byogene (BRA)
• Genex (BRA)
• Genera (BRA)
• Loccus (BRA)
• Eli Lily
• F. Hoffmann-La Roche
• Pfizer
• Johnson & Johnson
• Merck
• Novartis
• Amgen
• Astrazeneca

Healthcare Policies and Regulatory Landscape

The Sistema nico de Sade (SUS), a government-funded healthcare system that offers free access to a variety of medical services, including cancer treatments like chemotherapy, radiation therapy, and surgery, covers a major portion of the cost of cancer treatment in Brazil. Private health insurance alternatives are an alternative to the SUS and may offer additional coverage for cancer treatments, such as admission to private hospitals or more specialized care. Private health insurance, however, can be pricey and not available to all individuals. The Sistema de Informaçes sobre Orçamentos Pblicos em Sade (SIOPS) program, which provides funding for a variety of healthcare services, including cancer treatments, is run by the Brazilian government and deals with reimbursement procedures for cancer therapies. Treatments must be authorized by the Brazilian government's Agência Nacional de Vigilância Sanitária (ANVISA), which is in charge of overseeing the use of drugs and medical equipment. The Programa de Apoio ao Desenvolvimento Institucional do Sistema nico de Sade (PROADI-SUS) is a different initiative run by the Brazilian government that gives funds for the research and development of novel medical innovations, including cancer therapies.